tiprankstipranks
Mirum Pharmaceuticals Inc (DE:08D)
XETRA:08D
Germany Market
08D
Mirum Pharmaceuticals
RESEARCH TOOLSreports

Mirum Pharmaceuticals (08D) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

08D Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Mirum
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

08D Stock 12 Month Forecast

Average Price Target

€116.27
▲(38.45% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Mirum Pharmaceuticals in the last 3 months. The average price target is €116.27 with a high forecast of €124.79 and a low forecast of €101.55. The average price target represents a 38.45% change from the last price of €83.98.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"59":"€59","92":"€92","125":"€125","75.5":"€75.5","108.5":"€108.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":124.78764525,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€124.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":116.267661195,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€116.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":101.5513251,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€101.55</span>\n  </div></div>","useHTML":true}}],"tickPositions":[59,75.5,92,108.5,125],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85,88.06058809615385,91.12117619230769,94.18176428846154,97.24235238461539,100.30294048076922,103.36352857692307,106.42411667307692,109.48470476923077,112.54529286538461,115.60588096153846,118.6664690576923,121.72705715384615,{"y":124.78764525,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85,87.40520470730769,89.81040941461538,92.21561412192308,94.62081882923077,97.02602353653846,99.43122824384615,101.83643295115385,104.24163765846154,106.64684236576923,109.05204707307692,111.45725178038461,113.8624564876923,{"y":116.267661195,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85,86.27317885384615,87.54635770769231,88.81953656153846,90.09271541538462,91.36589426923076,92.63907312307693,93.91225197692307,95.18543083076923,96.45860968461538,97.73178853846154,99.00496739230769,100.27814624615385,{"y":101.5513251,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":61,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.32,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.06,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.3,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.94,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€124.79Average Price Target€116.27Lowest Price Target€101.55
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:08D
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
€120.48
Buy
43.47%
Upside
Reiterated
08/21/26
Mirum Reaffirmed as Top Pick on Zilurgisertib’s Differentiated FOP Profile; Ramakanth Maintains $140 Price Target
J.P. Morgan Analyst forecast on DE:08D
Jessica Fye
J.P. Morgan
J.P. Morgan
€101.55
Buy
20.92%
Upside
Reiterated
08/11/26
J.P. Morgan Keeps Their Buy Rating on Mirum Pharmaceuticals (MIRM)
TD Cowen Analyst forecast on DE:08D
Joseph Thome
TD Cowen
TD Cowen
€120.48
Buy
43.47%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM) and Encompass Health (NYSE: EHC)
Citizens JMP Analyst forecast on DE:08D
Jonathan Wolleben
Citizens JMP
Citizens JMP
€125.65→€117.9
Buy
40.39%
Upside
Reiterated
08/06/26
Mirum Pharmaceuticals price target lowered to $137 from $146 at CitizensMirum Pharmaceuticals price target lowered to $137 from $146 at Citizens
Morgan Stanley Analyst forecast on DE:08D
Michael Ulz
Morgan Stanley
Morgan Stanley
€129.09→€117.9
Buy
40.39%
Upside
Assigned
08/06/26
Morgan Stanley Remains a Buy on Mirum Pharmaceuticals (MIRM)
RBC Capital Analyst forecast on DE:08D
Lisa Walter
RBC Capital
RBC Capital
€127.37→€116.18
Buy
38.34%
Upside
Reiterated
08/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM), Zimmer Biomet Holdings (NYSE: ZBH) and Editas Medicine (NASDAQ: EDIT)
Stifel Nicolaus Analyst forecast on DE:08D
James Condulis
Stifel Nicolaus
Stifel Nicolaus
€117.04
Buy
39.37%
Upside
Reiterated
08/06/26
Stifel Nicolaus Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)
Robert W. Baird Analyst forecast on DE:08D
Brian Skorney
Robert W. Baird
Robert W. Baird
€111.02→€105.85
Buy
26.05%
Upside
Reiterated
08/06/26
Mirum Pharmaceuticals price target lowered to $123 from $129 at BairdMirum Pharmaceuticals price target lowered to $123 from $129 at Baird
Cantor Fitzgerald Analyst forecast on DE:08D
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
€120.48
Buy
43.47%
Upside
Assigned
08/05/26
Mirum Pharmaceuticals (MIRM) Gets a Buy from Cantor Fitzgerald
Citi Analyst forecast on DE:08D
Yigal Nochomovitz
Citi
Citi
€124.79
Buy
48.59%
Upside
Reiterated
06/14/26
Buy Rating Reiterated on Mirum Pharmaceuticals as Zilurgisertib Data De-Risk Pipeline; $145 Price Target Unchanged with ~46% Upside Potential
Wolfe Research Analyst forecast on DE:08D
Kalpit Patel
Wolfe Research
Wolfe Research
€124.79
Buy
48.59%
Upside
Initiated
05/19/26
Mirum Pharmaceuticals initiated with an Outperform at Wolfe ResearchMirum Pharmaceuticals initiated with an Outperform at Wolfe Research
Leerink Partners Analyst forecast on DE:08D
Mani Foroohar
Leerink Partners
Leerink Partners
€129.09→€132.53
Buy
57.82%
Upside
Reiterated
05/15/26
Leerink Partners Remains a Buy on Mirum Pharmaceuticals (MIRM)
Evercore ISI Analyst forecast on DE:08D
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
€116.18→€118.76
Buy
41.42%
Upside
Reiterated
05/07/26
Mirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISIMirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISI
Raymond James Analyst forecast on DE:08D
Ryan Deschner
Raymond James
Raymond James
€141.14→€142
Buy
69.09%
Upside
Reiterated
05/07/26
Mirum Pharmaceuticals price target raised to $165 from $164 at Raymond JamesMirum Pharmaceuticals price target raised to $165 from $164 at Raymond James
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:08D
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
€120.48
Buy
43.47%
Upside
Reiterated
08/21/26
Mirum Reaffirmed as Top Pick on Zilurgisertib’s Differentiated FOP Profile; Ramakanth Maintains $140 Price Target
J.P. Morgan Analyst forecast on DE:08D
Jessica Fye
J.P. Morgan
J.P. Morgan
€101.55
Buy
20.92%
Upside
Reiterated
08/11/26
J.P. Morgan Keeps Their Buy Rating on Mirum Pharmaceuticals (MIRM)
TD Cowen Analyst forecast on DE:08D
Joseph Thome
TD Cowen
TD Cowen
€120.48
Buy
43.47%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM) and Encompass Health (NYSE: EHC)
Citizens JMP Analyst forecast on DE:08D
Jonathan Wolleben
Citizens JMP
Citizens JMP
€125.65→€117.9
Buy
40.39%
Upside
Reiterated
08/06/26
Mirum Pharmaceuticals price target lowered to $137 from $146 at CitizensMirum Pharmaceuticals price target lowered to $137 from $146 at Citizens
Morgan Stanley Analyst forecast on DE:08D
Michael Ulz
Morgan Stanley
Morgan Stanley
€129.09→€117.9
Buy
40.39%
Upside
Assigned
08/06/26
Morgan Stanley Remains a Buy on Mirum Pharmaceuticals (MIRM)
RBC Capital Analyst forecast on DE:08D
Lisa Walter
RBC Capital
RBC Capital
€127.37→€116.18
Buy
38.34%
Upside
Reiterated
08/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM), Zimmer Biomet Holdings (NYSE: ZBH) and Editas Medicine (NASDAQ: EDIT)
Stifel Nicolaus Analyst forecast on DE:08D
James Condulis
Stifel Nicolaus
Stifel Nicolaus
€117.04
Buy
39.37%
Upside
Reiterated
08/06/26
Stifel Nicolaus Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)
Robert W. Baird Analyst forecast on DE:08D
Brian Skorney
Robert W. Baird
Robert W. Baird
€111.02→€105.85
Buy
26.05%
Upside
Reiterated
08/06/26
Mirum Pharmaceuticals price target lowered to $123 from $129 at BairdMirum Pharmaceuticals price target lowered to $123 from $129 at Baird
Cantor Fitzgerald Analyst forecast on DE:08D
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
€120.48
Buy
43.47%
Upside
Assigned
08/05/26
Mirum Pharmaceuticals (MIRM) Gets a Buy from Cantor Fitzgerald
Citi Analyst forecast on DE:08D
Yigal Nochomovitz
Citi
Citi
€124.79
Buy
48.59%
Upside
Reiterated
06/14/26
Buy Rating Reiterated on Mirum Pharmaceuticals as Zilurgisertib Data De-Risk Pipeline; $145 Price Target Unchanged with ~46% Upside Potential
Wolfe Research Analyst forecast on DE:08D
Kalpit Patel
Wolfe Research
Wolfe Research
€124.79
Buy
48.59%
Upside
Initiated
05/19/26
Mirum Pharmaceuticals initiated with an Outperform at Wolfe ResearchMirum Pharmaceuticals initiated with an Outperform at Wolfe Research
Leerink Partners Analyst forecast on DE:08D
Mani Foroohar
Leerink Partners
Leerink Partners
€129.09→€132.53
Buy
57.82%
Upside
Reiterated
05/15/26
Leerink Partners Remains a Buy on Mirum Pharmaceuticals (MIRM)
Evercore ISI Analyst forecast on DE:08D
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
€116.18→€118.76
Buy
41.42%
Upside
Reiterated
05/07/26
Mirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISIMirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISI
Raymond James Analyst forecast on DE:08D
Ryan Deschner
Raymond James
Raymond James
€141.14→€142
Buy
69.09%
Upside
Reiterated
05/07/26
Mirum Pharmaceuticals price target raised to $165 from $164 at Raymond JamesMirum Pharmaceuticals price target raised to $165 from $164 at Raymond James
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
AXGNAxoGen
ATECAlphatec Holdings
CABACabaletta Bio
ONCBeOne Medicines
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mirum Pharmaceuticals

3 Months
Michael UlzMorgan Stanley
Success Rate
15/20 ratings generated profit
75%
Average Return
+13.73%
Copying Michael Ulz's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +13.73% per trade.
1 Year
Jonathan WollebenCitizens JMP
Success Rate
22/23 ratings generated profit
96%
Average Return
+53.72%
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 95.65% of your transactions generating a profit, with an average return of +53.72% per trade.
2 Years
Jonathan WollebenCitizens JMP
Success Rate
22/23 ratings generated profit
96%
Average Return
+128.89%
Copying Jonathan Wolleben's trades and holding each position for 2 Years would result in 95.65% of your transactions generating a profit, with an average return of +128.89% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

08D Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
9
13
12
5
1
Buy
19
17
13
17
14
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
28
30
25
22
15
In the current month, 08D has received 15 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 08D average Analyst price target in the past 3 months is 116.27.
Each month's total comprises the sum of three months' worth of ratings.

08D Financial Forecast

08D Earnings Forecast

Next quarter’s earnings estimate for 08D is -€0.45 with a range of -€0.75 to -€0.26. The previous quarter’s EPS was -€0.91. 08D beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 08D has Performed in-line its overall industry.
Next quarter’s earnings estimate for 08D is -€0.45 with a range of -€0.75 to -€0.26. The previous quarter’s EPS was -€0.91. 08D beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 08D has Performed in-line its overall industry.

08D Sales Forecast

Next quarter’s sales forecast for 08D is €152.74M with a range of €146.26M to €155.83M. The previous quarter’s sales results were €151.18M. 08D beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 08D has Performed in-line its overall industry.
Next quarter’s sales forecast for 08D is €152.74M with a range of €146.26M to €155.83M. The previous quarter’s sales results were €151.18M. 08D beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 08D has Performed in-line its overall industry.

08D Stock Forecast FAQ

What is DE:08D’s average 12-month price target, according to analysts?
Based on analyst ratings, Mirum Pharmaceuticals Inc’s 12-month average price target is 116.27.
    What is DE:08D’s upside potential, based on the analysts’ average price target?
    Mirum Pharmaceuticals Inc has 38.45% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Mirum Pharmaceuticals Inc a Buy, Sell or Hold?
          Mirum Pharmaceuticals Inc has a consensus rating of Strong Buy, which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Mirum Pharmaceuticals Inc’s share price target?
            The average share price target for Mirum Pharmaceuticals Inc is 116.27. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €124.79 ,and the lowest forecast is €101.55. The average share price target represents 38.45% Increase from the current price of €83.98.
              What do analysts say about Mirum Pharmaceuticals Inc?
              Mirum Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of Mirum Pharmaceuticals Inc?
                To buy shares of DE:08D, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.